These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 22781608

  • 21. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 22. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Pagano A, Stipa E, Amadori S.
    Blood; 2001 Aug 15; 98(4):952-7. PubMed ID: 11493438
    [Abstract] [Full Text] [Related]

  • 23. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY, Zhang Z, Song LX, Gzhang X, Su JY, Li X, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 15; 20(4):941-4. PubMed ID: 22931660
    [Abstract] [Full Text] [Related]

  • 24. [Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura].
    Cui J, Zhu TN, Zou N, Chen M, Zhao YQ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb 15; 35(1):116-20. PubMed ID: 23469801
    [Abstract] [Full Text] [Related]

  • 25. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct 15; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 26. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun 15; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 27. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.
    Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, Zhang W, Li M, Tang F, Zhang X, Zeng X, Zhao Y, Zhang F.
    Rheumatology (Oxford); 2011 Sep 15; 50(9):1640-4. PubMed ID: 21571767
    [Abstract] [Full Text] [Related]

  • 28. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
    Tanai C, Iki S, Nakahara F, Iijima K, Usuki K, Kuwana M, Urabe A.
    Rinsho Ketsueki; 2004 Nov 15; 45(11):1181-6. PubMed ID: 15609684
    [Abstract] [Full Text] [Related]

  • 29. [Use of rituximab in resistant thrombocytopenic purpura].
    Zambrano-Velarde MA, de la O-Peña D, Chávez-Peña Q, Bedolla-Barajas M.
    Rev Med Inst Mex Seguro Soc; 2012 Nov 15; 50(2):203-8. PubMed ID: 22882991
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children.
    Dai WJ, Zhang RR, Yang XC, Yuan YF.
    Eur Rev Med Pharmacol Sci; 2015 Jul 15; 19(13):2379-83. PubMed ID: 26214772
    [Abstract] [Full Text] [Related]

  • 31. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR, Segel E, Brandsborg M, d'Amore F.
    Eur J Haematol; 2011 Mar 15; 86(3):256-9. PubMed ID: 21166717
    [Abstract] [Full Text] [Related]

  • 32. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
    Gall B, Yee A, Berry B, Bircham D, Hayashi A, Dansereau J, Hart J.
    J Obstet Gynaecol Can; 2010 Dec 15; 32(12):1167-1171. PubMed ID: 21176329
    [Abstract] [Full Text] [Related]

  • 33. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
    Julia A, Kovaleva L, Loria S, Alberca I, Hernandez F, Sandoval V, Sierra J, Vidaller A, Ayguasanosa J, Carretero M.
    Transfus Med; 2009 Oct 15; 19(5):260-8. PubMed ID: 19747289
    [Abstract] [Full Text] [Related]

  • 34. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.
    Mayo Clin Proc; 2003 Nov 15; 78(11):1340-6. PubMed ID: 14601692
    [Abstract] [Full Text] [Related]

  • 35. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
    Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB.
    Br J Haematol; 2012 Aug 15; 158(4):539-47. PubMed ID: 22775462
    [Abstract] [Full Text] [Related]

  • 36. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 15; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 37. [A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura].
    Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, Zhang M, Song SJ, Wang JM, Meng FY, Shan YD.
    Zhonghua Nei Ke Za Zhi; 2004 Aug 15; 43(8):608-10. PubMed ID: 15355668
    [Abstract] [Full Text] [Related]

  • 38. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
    Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM.
    Br J Haematol; 2013 Sep 15; 162(5):693-701. PubMed ID: 23829485
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
    Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, Durand JM.
    Ann Hematol; 2012 Feb 15; 91(2):279-85. PubMed ID: 21710166
    [Abstract] [Full Text] [Related]

  • 40. Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.
    Ansari Sh, Rostami T, Yousefian S, Kiumarsi A, Miri-Aliabad G, Ramim T.
    Pediatr Hematol Oncol; 2014 Sep 15; 31(6):555-62. PubMed ID: 25007304
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.